Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Human Immunodeficiency Virus Infection

Human Immunodeficiency Virus Infection

Subtypes of Human Immunodeficiency Virus Infection

AIDS-Related Anorexia 1 Human Immunodeficiency Virus 1 (HIV-1) 1

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Human Immunodeficiency Virus Infection

126 trials tracked for Human Immunodeficiency Virus Infection: 33 in phase 3 or 4 and 11 with published results. The most-cited published study has 379 citations.

126Trials tracked
33Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 10 Phase 3 23 Phase 2 28 Phase 1 14 Other / NA 51
  1. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1) Completed · 379 cited
  2. Phase 3 An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) Completed · 378 cited
  3. Phase 3 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection Completed · 305 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) Completed · 147 cited
  5. Phase 3 A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Completed · 118 cited
  6. Phase 3 Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women Completed · 111 cited
Show 44 more trials
  1. Phase 3 Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection Completed · 110 cited
  2. Phase 3 Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV Completed · 42 cited
  3. Phase 3 Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2) Completed · 40 cited
  4. Phase 4 A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers Completed · 35 cited
  5. Phase 3 Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa Completed
  6. Phase 4 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Completed
  7. Phase 4 Mobile Evidence-Based Smoking Cessation for Veterans Living With HIV (MESH) Completed
  8. Phase 4 HIV Non-Occupational Post-Exposure Prophylaxis Completed
  9. Phase 4 Maraviroc Efficacy for Hepatitis C Completed
  10. Phase 4 Biomarkers for Event-driven PrEP Adherence Completed
  11. Phase 4 Post-Exposure Prophylaxis in Health Care Workers Completed
  12. Phase 4 Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa Completed
  13. Phase 4 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed
  14. Phase 4 A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) Completed
  15. Phase 3 ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection Completed
  16. Phase 3 Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) Completed
  17. Phase 3 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults Completed
  18. Phase 3 A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. Completed
  19. Phase 3 A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects Completed
  20. Phase 3 A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055) Completed
  21. Phase 3 A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults Completed
  22. Phase 3 A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects Completed
  23. Phase 3 A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects Completed
  24. Phase 3 Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir Completed
  25. Phase 3 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults Completed
  26. Phase 3 A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Completed
  27. Phase 3 Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects Completed
  28. Phase 2 Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects Completed
  29. Phase 2 Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. Completed
  30. Phase 2 Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults Completed
  31. Phase 2 Dutch Acute HCV in HIV Study (DAHHS) Completed
  32. Phase 2 Effect of Evolocumab on Coronary Endothelial Function Completed
  33. Phase 2 Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR) Completed
  34. Phase 2 Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults. Completed
  35. Phase 2 A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir Completed
  36. Phase 2 Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women Completed
  37. Phase 2 HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections Completed
  38. Phase 2 Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection Completed
  39. Phase 2 Study to Evaluate a HIV Drug for the Treatment of HIV Infection Completed
  40. Phase 2 A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects Completed
  41. Phase 2 Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study Completed
  42. Phase 2 Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis Completed
  43. Phase 2 Effect of Cenicriviroc on HIV Neurocognitive Impairment Completed
  44. Phase 2 Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Completed

Showing the 50 most-cited and recently-updated of 126 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
MiniDock MTB Test Shows High Sensitivity and Specificity for Tuberculosis Detection
Pediatrics
MiniDock MTB Test Shows High Sensitivity and Specificity for Tuberculosis Detection A new test finds TB in people who cough up nothing
This prospective cross-sectional study evaluated the MiniDock MTB test using sputum and tongue swabs in 1380 patients with presumptive pulmo…
A new test found tuberculosis in over 85% of patients who could not produce a cough sample, offering a faster way to diagnose the disease in…
Apr 30, 2026
Narrative review on ICIs in patients with viral infections and solid tumors
Allergy & Immunology Sys. Review
Narrative review on ICIs in patients with viral infections and solid tumors Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors.
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Frontiers Apr 27, 2026
HIV outbreak identified among persons who inject drugs in Cabell County, West Virginia
Allergy & Immunology
HIV outbreak identified among persons who inject drugs in Cabell County, West Virginia Health officials report HIV outbreak among people who inject drugs in West Virginia
A field report describes an HIV outbreak among persons who inject drugs in Cabell County, West Virginia.
HIV outbreak among people who inject drugs in West Virginia highlights urgent need for prevention and care in communities with high substanc…
CDC Apr 4, 2026
Index testing increases HIV testing and diagnoses among contacts in 20 CDC-supported countries
Allergy & Immunology
Index testing increases HIV testing and diagnoses among contacts in 20 CDC-supported countries When health workers test the contacts of HIV patients, do more people get diagnosed?
An observational report from 20 CDC-supported countries found that scaling up index testing among contacts of HIV-positive patients was asso…
Testing partners of newly diagnosed HIV patients led to more people getting tested and finding out their status in 20 countries.
CDC Apr 4, 2026
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1
Allergy & Immunology Phase III
Phase 3 trial compares switch to doravirine/islatravir versus continuing bictegravir/FTC/TAF in HIV-1 Phase 3 trial compares two HIV drug regimens for people already virologically suppressed
A phase 3 randomized controlled trial enrolled 643 virologically suppressed adults with HIV-1 to compare switching to doravirine/islatravir …
People with HIV already on effective treatment can safely switch to a new two-drug pill without losing virus control, according to a complet…
CT.gov Apr 2, 2026
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting
Oncology FDA Approval
FDA Approves Marinol (dronabinol) for AIDS-Related Anorexia and Chemotherapy-Induced Nausea/Vomiting FDA approves a new drug called Marinol to help with AIDS-related weight loss and chemotherapy nausea
The FDA has approved Marinol (dronabinol) for two indications in adults: anorexia associated with weight loss in patients with AIDS, and nau…
The FDA approved Marinol to treat AIDS-related weight loss and severe chemotherapy nausea that standard treatments couldn't control.
FDA Mar 31, 2026

Questions about Human Immunodeficiency Virus Infection

What happened during the HIV outbreak among drug injectors in Cabell County?

An HIV outbreak occurred among people who inject drugs in Cabell County, West Virginia, highlighting the need for better prevention and care in communities with high substance use.

Full answer →